These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 17868455)
1. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biederman J; Mick EO; Surman C; Doyle R; Hammerness P; Michel E; Martin J; Spencer TJ BMC Psychiatry; 2007 Sep; 7():49. PubMed ID: 17868455 [TBL] [Abstract][Full Text] [Related]
2. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Wolraich ML; Greenhill LL; Pelham W; Swanson J; Wilens T; Palumbo D; Atkins M; McBurnett K; Bukstein O; August G Pediatrics; 2001 Oct; 108(4):883-92. PubMed ID: 11581440 [TBL] [Abstract][Full Text] [Related]
3. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder. Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder. Wigal SB; Gupta S; Heverin E; Starr HL J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):255-63. PubMed ID: 21663428 [TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biederman J; Mick E; Surman C; Doyle R; Hammerness P; Harpold T; Dunkel S; Dougherty M; Aleardi M; Spencer T Biol Psychiatry; 2006 May; 59(9):829-35. PubMed ID: 16373066 [TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan. Takahashi N; Koh T; Tominaga Y; Saito Y; Kashimoto Y; Matsumura T World J Biol Psychiatry; 2014 Aug; 15(6):488-98. PubMed ID: 24456065 [TBL] [Abstract][Full Text] [Related]
7. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Steele M; Weiss M; Swanson J; Wang J; Prinzo RS; Binder CE Can J Clin Pharmacol; 2006; 13(1):e50-62. PubMed ID: 16456216 [TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. Riggs PD; Winhusen T; Davies RD; Leimberger JD; Mikulich-Gilbertson S; Klein C; Macdonald M; Lohman M; Bailey GL; Haynes L; Jaffee WB; Haminton N; Hodgkins C; Whitmore E; Trello-Rishel K; Tamm L; Acosta MC; Royer-Malvestuto C; Subramaniam G; Fishman M; Holmes BW; Kaye ME; Vargo MA; Woody GE; Nunes EV; Liu D J Am Acad Child Adolesc Psychiatry; 2011 Sep; 50(9):903-14. PubMed ID: 21871372 [TBL] [Abstract][Full Text] [Related]
9. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. Gau SS; Shen HY; Soong WT; Gau CS J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):441-55. PubMed ID: 16958569 [TBL] [Abstract][Full Text] [Related]
10. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386 [TBL] [Abstract][Full Text] [Related]
11. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study. Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533 [TBL] [Abstract][Full Text] [Related]
12. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH. Kordon A; Stollhoff K; Niederkirchner K; Mattejat F; Rettig K; Schäuble B Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting. Silva R; Muniz R; Pestreich LK; Brams M; Childress A; Lopez FA J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):637-54. PubMed ID: 16190795 [TBL] [Abstract][Full Text] [Related]
15. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pelham WE; Gnagy EM; Burrows-Maclean L; Williams A; Fabiano GA; Morrisey SM; Chronis AM; Forehand GL; Nguyen CA; Hoffman MT; Lock TM; Fielbelkorn K; Coles EK; Panahon CJ; Steiner RL; Meichenbaum DL; Onyango AN; Morse GD Pediatrics; 2001 Jun; 107(6):E105. PubMed ID: 11389303 [TBL] [Abstract][Full Text] [Related]
16. Prospective, naturalistic study of open-label OROS methylphenidate treatment in Chinese school-aged children with attention-deficit/hyperactivity disorder. Zheng Y; Wang YF; Qin J; Wang LW; Zou LP; Jin XM; Xu T; Wang Y; Qi YL; Gong ME; Yin QY; Mai JN; Jing J; Luo XY; Ma HW; Li HB; Xie L; Li Y; Kuang GF; Yi MJ; Wang F; Zhu XH; Yao YB Chin Med J (Engl); 2011 Oct; 124(20):3269-74. PubMed ID: 22088519 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study. Casas M; Rösler M; Sandra Kooij JJ; Ginsberg Y; Ramos-Quiroga JA; Heger S; Berwaerts J; Dejonckheere J; van der Vorst E; Schäuble B World J Biol Psychiatry; 2013 May; 14(4):268-81. PubMed ID: 22106853 [TBL] [Abstract][Full Text] [Related]
18. Are stimulants effective in the treatment of executive function deficits? Results from a randomized double blind study of OROS-methylphenidate in adults with ADHD. Biederman J; Mick E; Fried R; Wilner N; Spencer TJ; Faraone SV Eur Neuropsychopharmacol; 2011 Jul; 21(7):508-15. PubMed ID: 21303732 [TBL] [Abstract][Full Text] [Related]
19. Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study. Remschmidt H; Hoare P; Ettrich C; Rothenberger A; Santosh P; Schmidt M; Spender Q; Tamhne R; Thompson M; Tinline C; Trott GE; Medori R Eur Child Adolesc Psychiatry; 2005 Sep; 14(6):297-304. PubMed ID: 16220213 [TBL] [Abstract][Full Text] [Related]
20. 12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH. Hoare P; Remschmidt H; Medori R; Ettrich C; Rothenberger A; Santosh P; Schmit M; Spender Q; Tamhne R; Thompson M; Tinline C; Trott GE Eur Child Adolesc Psychiatry; 2005 Sep; 14(6):305-9. PubMed ID: 16220214 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]